Essex Bio-Technology Limited

1061

KYG312371035

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
2.19 ^HKD	0.00%		-5.19%	-12.05%

Mar. 19	Essex Bio-Technology's 2023 Profit Jumps 22% on Higher Turnover	MT
Mar. 18	Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024	CI

Essex Bio-Technology Limited Announces Change of Address of Head Office And principal Place of Business in Hong Kong

January 03, 2024 at 04:08 am EST

The board of directors of Essex Bio-Technology Limited announced that the address of head office and principal place of business in Hong Kong of the Company has been changed from Room 2818, China Merchants Tower, Shun Tak Centre, 168-200 Connaught Road Central, Hong Kong to Room 3206, West Tower, Shun Tak Centre, 168-200 Connaught Road, Hong Kong with effect from 3 January 2024.

Latest news about Essex Bio-Technology Limited

Essex Bio-Technology's 2023 Profit Jumps 22% on Higher Turnover	Mar. 19	MT
Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024	Mar. 18	CI
Essex Bio-Technology Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Essex Bio-Technology Limited Announces Change of Address of Head Office And principal Place of Business in Hong Kong	Jan. 03	CI
Essex Bio-Technology Limited(SEHK:1061) dropped from S&P Global BMI Index	23-09-18	CI
Essex Bio-Technology's Profit Jumps 22% in H1	23-08-17	MT
Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 13, 2023	23-08-16	CI
Essex Bio-Technology Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-16	CI
Essex Bio-Technology's Ophthalmic Injection Showed Safety, Efficacy in Trial	23-07-27	MT
Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative Age-Related Macular Degeneration	23-07-26	CI
Essex Bio-Technology Limited Announces Early Repayment of Loan Facility	23-07-17	CI
Essex Bio-Technology Limited commences an Equity Buyback Plan for 57,064,900 shares, representing 10% of its issued share capital, under the authorization approved on June 9, 2023.	23-06-13	CI
Essex Bio-Technology Limited Announces Director Changes	23-06-09	CI
Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022	23-06-09	CI
Essex Bio-Technology Limited's Equity Buyback announced on May 12, 2022 has expired.	23-06-08	CI
Essex Bio-Technology Slashes Final Dividend as 2022 Profit Falls	23-03-09	MT
Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022, Payable on 29 June 2023	23-03-08	CI
Tranche Update on Essex Bio-Technology Limited's Equity Buyback Plan announced on May 12, 2022.	23-03-08	CI
Essex Bio-Technology Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-08	CI
Correction: Henlius Biotech, Essex Bio-Tech Dose First Patient for Ophthalmic Drug Trial in the US	23-02-10	MT
Essex Bio-Technology Limited Completes First Patient First Dose in the United States in an International Multi-Centre Phase 3 Clinical Study	23-02-10	CI
Essex Bio-Technology Expects 35% Fall in 2022 Profit; Shares Slip 3%	23-01-10	MT
Essex Bio-Technology Limited Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended 31 December 2022	23-01-10	CI
Essex Bio-Technology Unit Secures Patent License from Mitotech	22-10-13	MT
Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on September 21, 2022	22-08-23	CI

Chart Essex Bio-Technology Limited

Duration

Period

More charts

Company Profile

Essex Bio-Technology Ltd is an investment holding company principally engaged in the manufacture and sales of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds. The Company develops biopharmaceutical drugs based on recombinant deoxyribonucleic acid (DNA) technology. The main brands of the Company's products are Beifuji, Beifushu and Beifuxin. The Company operates through two segments. The Surgical segment is engaged in the manufacture and sale of Beifuji spray, Beifuji lyophilised powder and Beifuxin gel. The Ophthalmology segment is engaged in the manufacture and sale of Beifushu eye drops, Beifushu eye gel and Beifushu unit-dose eye drops.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
ESSEX BIO-TECHNOLOGY LIMITED	-12.05%	159M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals